The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
Published version of a preprint
Abstract
We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 and 6, in a multicenter study including phase I dose escalation followed by tumor-specific cohorts for breast cancer, non–small cell lung cancer (NSCLC), glioblastoma, melanoma, and colorectal cancer. A total of 225 patients were enrolled: 33 in dose escalation and 192 in tumor-specific cohorts. Dose-limiting toxicity was grade 3 fatigue. The maximum tolerated dose was 200 mg every 12 hours. The most common possibly related treatment-emergent adverse events involved fatigue and the gastrointestinal, renal, or hematopoietic systems. Plasma concentrations increased with dose, and pharmacodynamic effects were observed in proliferating keratinocytes and tumors. Radiographic responses were achieved in previously treated patients with breast cancer, NSCLC, and melanoma. For hormone receptor–positive breast cancer, the overall response rate was 31%; moreover, 61% of patients achieved either response or stable disease lasting ≥6 months. Significance: Abemaciclib represents the first selective inhibitor of CDK4 and CDK6 with a safety profile allowing continuous dosing to achieve sustained target inhibition. This first-in-human experience demonstrates single-agent activity for patients with advanced breast cancer, NSCLC, and other solid tumors. Cancer Discov; 6(7); 740–53. ©2016 AACR. See related commentary by Lim et al., p. 697. This article is highlighted in the In This Issue feature, p. 681
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CDK4 and 6 (CDK4/6) inhibitors, a class of promising anticancer agents, showed therapeutic efficacy against KRAS-mutant solid tumors, including NSCLC and CRC [125].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [125]
In the citing paper
“CDK4, one of the main controllers of cell cycle entry, is substantially overexpressed in glioblastoma, breast and ovarian cancers, making it an attractive therapeutic target27, 28, 29.”
In the citing paper
“In the few human patients receiving abemaciclib, in which drug levels in the central nervous system were measured, accumulations in the range of 2.2–14.7 nmol/L were achieved (Patnaik et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Patnaik et al., 2016
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Morgan, D. O. (1995) · Nature · doi:10.1038/374131a0 · Cited by 3,284
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Forging a signature of in vivo senescence
Sharpless, N. E., & Sherr, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3960 · Cited by 1,104
Living with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Self-citationTargeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Self-citationSkoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
(1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60352-8 · Cited by 752
Mouse development and cell proliferation in the absence of D-cyclins
Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647
Rustin, G. J. S., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., du Bois, A., Kristensen, G., Jakobsen, A., Sagae, S., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182070f17 · Cited by 625
Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577
Self-citationVan Allen, E. M., Wagle, N., Stojanov, P., Perrin, D. L., Cibulskis, K., Marlow, S., Jane-Valbuena, J., Friedrich, D. C., Kryukov, G., Carter, S. L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3559 · Cited by 546
Self-citationAnders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
Inhibition of Ras-Induced Proliferation and Cellular Transformation by p16 INK4
Serrano, M., Gómez-Lahoz, E., DePinho, R. A., Beach, D., & Bar-Sagi, D. (1995) · Science · doi:10.1126/science.7809631 · Cited by 373
Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0509 · Cited by 366
Self-citationDeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., Colameco, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2258 · Cited by 343
The Requirement for Cyclin D Function in Tumor Maintenance
Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342
Raub, T. J., Wishart, G. N., Kulanthaivel, P., Staton, B. A., Ajamie, R. T., Sawada, G. A., Gelbert, L. M., Shannon, H. E., Sanchez-Martinez, C., & De Dios, A. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062745 · Cited by 284
Self-citationThe Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Sheppard, K. E., & McArthur, G. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0259 · Cited by 265
Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260
Cell cycle control in breast cancer cells
Caldon, C. E., Daly, R. J., Sutherland, R. L., & Musgrove, E. A. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20690 · Cited by 238
The INK4 Family of CDK Inhibitors
Carnero, A., & Hannon, G. J. (1998) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-71941-7_3 · Cited by 186
Zou, X., Ray, D., Aziyu, A., Christov, K. T., Boiko, A. D., Gudkov, A. V., & Kiyokawa, H. (2002) · Genes & Development · doi:10.1101/gad.1033002 · Cited by 159
Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S.-B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0257 · Cited by 132
Self-citationTate, S. C., Cai, S., Ajamie, R. T., Burke, T., Beckmann, R. P., Chan, E. M., De Dios, A., Wishart, G. N., Gelbert, L. M., & Cronier, D. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2846 · Cited by 130
Self-citationCalles, A., Sholl, L. M., Rodig, S. J., Pelton, A. K., Hornick, J. L., Butaney, M., Lydon, C., Dahlberg, S. E., Oxnard, G. R., Jackman, D. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3112 · Cited by 115
Cyclin-Dependent Kinase 4 Expression Is Essential for Neu-Induced Breast Tumorigenesis
Reddy, H. K. D. L., Mettus, R. V., Rane, S. G., Graña, X., Litvin, J., & Reddy, E. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2639 · Cited by 108
Kim, S., Loo, A., Chopra, R., Caponigro, G., Huang, A., Vora, S., Parasuraman, S., Howard, S., Keen, N., Sellers, W., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-pr02 · Cited by 106
Dai, C. Y., Furth, E. E., Mick, R., Koh, J., Takayama, T., Niitsu, Y., & Enders, G. H. (2000) · Gastroenterology · doi:10.1053/gast.2000.17952 · Cited by 100
Guan, J.-L., Zhong, W.-Z., An, S.-J., Yang, J.-J., Su, J., Chen, Z.-H., Yan, H.-H., Chen, Z.-Y., Huang, Z.-M., Zhang, X.-C., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2754-z · Cited by 87
Alteration of cell-cycle regulation in epithelial ovarian cancer
Nam, E. J., & Kim, Y. T. (2008) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2008.01191.x · Cited by 77
Infante, J. R., Shapiro, G. I., Witteveen, P. O., Gerecitano, J. F., Ribrag, V., Chugh, R., Chakraborty, A., Matano, A., Zhao, X., Parasuraman, S., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-a276 · Cited by 16
Self-citation
Cited by
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Self-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
“Preclinical evaluation demonstrated the antitumor activity of abemaciclib in an ER+/human epidermal growth factor receptor 2-negative (HER2−) breast cancer xenograft model.(10) In the phase I setting, abemaciclib demonstrated activity in HR+ mBC as monotherapy and in combination with fulvestrant.”
BackgroundResultInfluentialSelf-citationSmall molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
CDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Metadata
- Authors
- Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., Nasir, A., Beckmann, R. P., Schade, A. E., Fulford, A. D., Nguyen, T. S., Martinez, R., Kulanthaivel, P., Li, L. Q., Frenzel, M., Cronier, D. M., Chan, E. M., Flaherty, K. T., Wen, P. Y., & Shapiro, G. I.
- Affiliations
- South Texas Accelerated Research Therapeutics (US)
- University of California, Los Angeles (US)
- Dana-Farber Cancer Institute (US)
- Eli Lilly (United States) (US)
- 4Eli Lilly and Company, Indianapolis, Indiana.
- Massachusetts General Hospital (US)
- Corresponding author
- Patnaik, Amita
- ORCID
- Venue
- Cancer Discovery
- Published
- 2016-06-30
- Volume
- 6
- Issue
- 7
- Pages
- 740-753
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2402797587
- Cited by
- 743
- References
- 48
- Citations by year
- 2026: 42 · 2025: 76 · 2024: 45 · 2023: 80 · 2022: 78 · 2021: 100 · 2020: 91 · 2019: 67 · 2018: 79 · 2017: 73 · 2016: 12
- FWCI
- 68.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- abemaciclib, CDK4/6 inhibitors, cyclin-dependent kinases, breast cancer, non-small cell lung cancer, melanoma, glioblastoma, colorectal cancer, solid tumors, pharmacokinetics, pharmacodynamics, dose-limiting toxicity, fatigue, hormone receptor-positive breast cancer, anticancer activity, monotherapy
- MeSH terms
- Aminopyridines, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Disease Models, Animal, Female, Humans, Lung Neoplasms, Male, Neoplasm Metastasis, Neoplasm Staging, Neoplasms, Tomography, X-Ray Computed, Treatment Outcome, Drug Monitoring, Xenograft Model Antitumor Assays, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.